Amgen stock price jumps as earnings beat puts MariTide obesity bet back in focus
New York, Feb 4, 2026, 15:19 EST — Regular session
- Amgen shares surged roughly 9% in afternoon trading, defying the weaker trend seen across the broader market
- Investors weighed the 2026 outlook as well as the latest on obesity drug MariTide
- FDA resistance to the rare-disease drug Tavneos continues to weigh on sentiment
Shares of Amgen Inc climbed 8.5%, reaching $367.52 in afternoon trading, bucking a decline in the S&P 500 and a wider fall in biotech stocks.
This shift matters because Amgen’s future growth hinges less on its established products and more on the pipeline’s ability to compensate as prices fall and generic rivals multiply.
The report arrives amid a jam-packed earnings day for U.S….
